15:14 IST
BSE
Other Announcement
Sandu Pharmaceuticals Other Announcement
Sandu Pharmaceuticals has appointed M/s. Dave & Dave as Statutory Auditors for a five-year term, following the tenure expiry of the previous auditors.
Sandu Pharmaceuticals Ltd
- Share price
- ₹36.82
- Market cap
- ₹35.57 Cr
- Revenue (annual)
- ₹69.93 Cr
- Net profit (annual)
- ₹1.77 Cr
- P/E (TTM)
- 14.6×Sector 47.4×
- Promoter holding
- 37.79%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Other Announcement 6Financial Results 3Board Meeting Date 3Management Change 2Annual General Meeting 2Legal & Regulatory 1Fund Raise 1Dividend 1Debt & Borrowing 1Annual Report 1
Time
6 announcements with these filters
17:41 IST
BSE
Other Announcement
Sandu Pharmaceuticals Other Announcement
Sandu Pharmaceuticals Ltd issued a letter to shareholders whose email addresses are not registered, providing the weblink to the Annual Report for FY 2026-27.
18:38 IST
BSE
Other Announcement
Sandu Pharmaceuticals Other Announcement
Sandu Pharmaceuticals Limited filed its quarterly Statement of Deviation or Variation in utilization of funds for the quarter ended June 30, 2026. No deviation or variation was reported.
10:52 IST
BSE
Other Announcement
Sandu Pharmaceuticals Other Announcement
Sandu Pharmaceuticals filed its Annual Secretarial Compliance Report for the year ended March 2026. The auditor confirmed general regulatory compliance with minor previous reporting delays noted.
18:38 IST
BSE
Other Announcement
Sandu Pharmaceuticals Other Announcement
Sandu Pharmaceuticals Ltd confirmed it is not classified as a 'Large Corporate' under SEBI's debt-raising framework for FY 2025-26. The company reported zero outstanding and incremental borrowings for the period ending March 31, 2026.
11:59 IST
BSE
Other Announcement
Sandu Pharmaceuticals Other Announcement
Sandu Pharmaceuticals Limited submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The company confirmed that securities received for dematerialisation during the quarter ended March 31, 2026, were processed and listed on the exchange. This is a routine regulatory filing with no material financial impact.